Dental Patient Care America, Inc.
Dental Patient Care America, Inc. (DPAT) Stock Competitors & Peer Comparison
See (DPAT) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Care Facilities Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DPAT | $0.02 | +0.00% | 481.6K | -2.00 | -$0.01 | N/A |
| FSNUY | $14.10 | +1.66% | 126.9B | 23.87 | $0.59 | +1.95% |
| FSNUF | $56.35 | +0.00% | 31.7B | 23.98 | $2.35 | +1.87% |
| JDHIF | $8.30 | +0.00% | 26.5B | 39.50 | $0.21 | N/A |
| JDHIY | $6.82 | +0.00% | 21.8B | 32.48 | $0.21 | N/A |
| FMCQF | $51.00 | +0.00% | 15B | 19.62 | $2.60 | +3.20% |
| BDUUY | $32.33 | +0.00% | 12.8B | 28.36 | $1.14 | +2.79% |
| IHHHF | $1.19 | +0.00% | 10.5B | 17.00 | $0.07 | +4.88% |
| BDULF | $0.62 | +1.17% | 9.9B | 20.71 | $0.03 | +3.57% |
| BDUUF | $0.59 | +0.00% | 9.4B | 19.67 | $0.03 | +3.76% |
Stock Comparison
DPAT vs FSNUY Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, FSNUY has a market cap of 126.9B. Regarding current trading prices, DPAT is priced at $0.02, while FSNUY trades at $14.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas FSNUY's P/E ratio is 23.87. In terms of profitability, DPAT's ROE is +0.45%, compared to FSNUY's ROE of +0.06%. Regarding short-term risk, DPAT is less volatile compared to FSNUY. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check FSNUY's competition here
DPAT vs FSNUF Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, FSNUF has a market cap of 31.7B. Regarding current trading prices, DPAT is priced at $0.02, while FSNUF trades at $56.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas FSNUF's P/E ratio is 23.98. In terms of profitability, DPAT's ROE is +0.45%, compared to FSNUF's ROE of +0.06%. Regarding short-term risk, DPAT is less volatile compared to FSNUF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check FSNUF's competition here
DPAT vs JDHIF Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, JDHIF has a market cap of 26.5B. Regarding current trading prices, DPAT is priced at $0.02, while JDHIF trades at $8.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas JDHIF's P/E ratio is 39.50. In terms of profitability, DPAT's ROE is +0.45%, compared to JDHIF's ROE of +0.08%. Regarding short-term risk, DPAT is less volatile compared to JDHIF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check JDHIF's competition here
DPAT vs JDHIY Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, JDHIY has a market cap of 21.8B. Regarding current trading prices, DPAT is priced at $0.02, while JDHIY trades at $6.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas JDHIY's P/E ratio is 32.48. In terms of profitability, DPAT's ROE is +0.45%, compared to JDHIY's ROE of +0.08%. Regarding short-term risk, DPAT is less volatile compared to JDHIY. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check JDHIY's competition here
DPAT vs FMCQF Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, FMCQF has a market cap of 15B. Regarding current trading prices, DPAT is priced at $0.02, while FMCQF trades at $51.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas FMCQF's P/E ratio is 19.62. In terms of profitability, DPAT's ROE is +0.45%, compared to FMCQF's ROE of +0.05%. Regarding short-term risk, DPAT is less volatile compared to FMCQF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check FMCQF's competition here
DPAT vs BDUUY Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, BDUUY has a market cap of 12.8B. Regarding current trading prices, DPAT is priced at $0.02, while BDUUY trades at $32.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas BDUUY's P/E ratio is 28.36. In terms of profitability, DPAT's ROE is +0.45%, compared to BDUUY's ROE of +0.16%. Regarding short-term risk, DPAT is less volatile compared to BDUUY. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check BDUUY's competition here
DPAT vs IHHHF Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, IHHHF has a market cap of 10.5B. Regarding current trading prices, DPAT is priced at $0.02, while IHHHF trades at $1.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas IHHHF's P/E ratio is 17.00. In terms of profitability, DPAT's ROE is +0.45%, compared to IHHHF's ROE of +0.08%. Regarding short-term risk, DPAT and IHHHF have similar daily volatility (0.00).Check IHHHF's competition here
DPAT vs BDULF Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, BDULF has a market cap of 9.9B. Regarding current trading prices, DPAT is priced at $0.02, while BDULF trades at $0.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas BDULF's P/E ratio is 20.71. In terms of profitability, DPAT's ROE is +0.45%, compared to BDULF's ROE of +0.16%. Regarding short-term risk, DPAT is less volatile compared to BDULF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check BDULF's competition here
DPAT vs BDUUF Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, BDUUF has a market cap of 9.4B. Regarding current trading prices, DPAT is priced at $0.02, while BDUUF trades at $0.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas BDUUF's P/E ratio is 19.67. In terms of profitability, DPAT's ROE is +0.45%, compared to BDUUF's ROE of +0.16%. Regarding short-term risk, DPAT is less volatile compared to BDUUF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check BDUUF's competition here
DPAT vs WFHG Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, WFHG has a market cap of 6.7B. Regarding current trading prices, DPAT is priced at $0.02, while WFHG trades at $105.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas WFHG's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to WFHG's ROE of +0.28%. Regarding short-term risk, DPAT is less volatile compared to WFHG. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check WFHG's competition here
DPAT vs RMSYF Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, RMSYF has a market cap of 5.9B. Regarding current trading prices, DPAT is priced at $0.02, while RMSYF trades at $25.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas RMSYF's P/E ratio is 510.20. In terms of profitability, DPAT's ROE is +0.45%, compared to RMSYF's ROE of +0.01%. Regarding short-term risk, DPAT is less volatile compared to RMSYF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check RMSYF's competition here
DPAT vs RMYHY Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, RMYHY has a market cap of 5.7B. Regarding current trading prices, DPAT is priced at $0.02, while RMYHY trades at $5.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas RMYHY's P/E ratio is 571.00. In terms of profitability, DPAT's ROE is +0.45%, compared to RMYHY's ROE of +0.01%. Regarding short-term risk, DPAT and RMYHY have similar daily volatility (0.00).Check RMYHY's competition here
DPAT vs ANHGY Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, ANHGY has a market cap of 4B. Regarding current trading prices, DPAT is priced at $0.02, while ANHGY trades at $5.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas ANHGY's P/E ratio is 23.87. In terms of profitability, DPAT's ROE is +0.45%, compared to ANHGY's ROE of N/A. Regarding short-term risk, DPAT and ANHGY have similar daily volatility (0.00).Check ANHGY's competition here
DPAT vs BUHPF Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, BUHPF has a market cap of 3.9B. Regarding current trading prices, DPAT is priced at $0.02, while BUHPF trades at $4.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas BUHPF's P/E ratio is 17.96. In terms of profitability, DPAT's ROE is +0.45%, compared to BUHPF's ROE of +0.27%. Regarding short-term risk, DPAT is less volatile compared to BUHPF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check BUHPF's competition here
DPAT vs BUGDF Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, BUGDF has a market cap of 3.4B. Regarding current trading prices, DPAT is priced at $0.02, while BUGDF trades at $4.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas BUGDF's P/E ratio is 16.27. In terms of profitability, DPAT's ROE is +0.45%, compared to BUGDF's ROE of +0.27%. Regarding short-term risk, DPAT is less volatile compared to BUGDF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check BUGDF's competition here
DPAT vs MCVEF Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, MCVEF has a market cap of 3B. Regarding current trading prices, DPAT is priced at $0.02, while MCVEF trades at $19.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas MCVEF's P/E ratio is 82.63. In terms of profitability, DPAT's ROE is +0.45%, compared to MCVEF's ROE of +0.09%. Regarding short-term risk, DPAT is less volatile compared to MCVEF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check MCVEF's competition here
DPAT vs ORPEF Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, ORPEF has a market cap of 2.3B. Regarding current trading prices, DPAT is priced at $0.02, while ORPEF trades at $14.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas ORPEF's P/E ratio is 0.03. In terms of profitability, DPAT's ROE is +0.45%, compared to ORPEF's ROE of -0.23%. Regarding short-term risk, DPAT is less volatile compared to ORPEF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check ORPEF's competition here
DPAT vs MCVEY Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, MCVEY has a market cap of 2.2B. Regarding current trading prices, DPAT is priced at $0.02, while MCVEY trades at $16.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas MCVEY's P/E ratio is 40.37. In terms of profitability, DPAT's ROE is +0.45%, compared to MCVEY's ROE of +0.09%. Regarding short-term risk, DPAT is less volatile compared to MCVEY. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check MCVEY's competition here
DPAT vs TTALF Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, TTALF has a market cap of 1.6B. Regarding current trading prices, DPAT is priced at $0.02, while TTALF trades at $12.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas TTALF's P/E ratio is 19.33. In terms of profitability, DPAT's ROE is +0.45%, compared to TTALF's ROE of +0.16%. Regarding short-term risk, DPAT and TTALF have similar daily volatility (0.00).Check TTALF's competition here
DPAT vs RAFLF Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, RAFLF has a market cap of 1.5B. Regarding current trading prices, DPAT is priced at $0.02, while RAFLF trades at $0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas RAFLF's P/E ratio is 26.67. In terms of profitability, DPAT's ROE is +0.45%, compared to RAFLF's ROE of +0.03%. Regarding short-term risk, DPAT is less volatile compared to RAFLF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check RAFLF's competition here
DPAT vs RHCGF Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, RHCGF has a market cap of 1.5B. Regarding current trading prices, DPAT is priced at $0.02, while RHCGF trades at $1.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas RHCGF's P/E ratio is -3.99. In terms of profitability, DPAT's ROE is +0.45%, compared to RHCGF's ROE of -0.07%. Regarding short-term risk, DPAT is less volatile compared to RHCGF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check RHCGF's competition here
DPAT vs RYHTY Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, RYHTY has a market cap of 1.4B. Regarding current trading prices, DPAT is priced at $0.02, while RYHTY trades at $6.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas RYHTY's P/E ratio is -3.86. In terms of profitability, DPAT's ROE is +0.45%, compared to RYHTY's ROE of -0.02%. Regarding short-term risk, DPAT and RYHTY have similar daily volatility (0.00).Check RYHTY's competition here
DPAT vs LWSCF Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, LWSCF has a market cap of 1.2B. Regarding current trading prices, DPAT is priced at $0.02, while LWSCF trades at $13.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas LWSCF's P/E ratio is 46.71. In terms of profitability, DPAT's ROE is +0.45%, compared to LWSCF's ROE of +0.06%. Regarding short-term risk, DPAT and LWSCF have similar daily volatility (0.00).Check LWSCF's competition here
DPAT vs LTGHY Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, LTGHY has a market cap of 1.1B. Regarding current trading prices, DPAT is priced at $0.02, while LTGHY trades at $3.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas LTGHY's P/E ratio is -20.67. In terms of profitability, DPAT's ROE is +0.45%, compared to LTGHY's ROE of +0.40%. Regarding short-term risk, DPAT is less volatile compared to LTGHY. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check LTGHY's competition here
DPAT vs LTGHF Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, LTGHF has a market cap of 1.1B. Regarding current trading prices, DPAT is priced at $0.02, while LTGHF trades at $0.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas LTGHF's P/E ratio is -19.69. In terms of profitability, DPAT's ROE is +0.45%, compared to LTGHF's ROE of +0.40%. Regarding short-term risk, DPAT is less volatile compared to LTGHF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check LTGHF's competition here
DPAT vs RHKJF Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, RHKJF has a market cap of 1B. Regarding current trading prices, DPAT is priced at $0.02, while RHKJF trades at $15.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas RHKJF's P/E ratio is 21.55. In terms of profitability, DPAT's ROE is +0.45%, compared to RHKJF's ROE of +0.03%. Regarding short-term risk, DPAT is less volatile compared to RHKJF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check RHKJF's competition here
DPAT vs RKAGY Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, RKAGY has a market cap of 986.6M. Regarding current trading prices, DPAT is priced at $0.02, while RKAGY trades at $7.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas RKAGY's P/E ratio is 22.33. In terms of profitability, DPAT's ROE is +0.45%, compared to RKAGY's ROE of +0.03%. Regarding short-term risk, DPAT is less volatile compared to RKAGY. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check RKAGY's competition here
DPAT vs NWKHY Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, NWKHY has a market cap of 961.4M. Regarding current trading prices, DPAT is priced at $0.02, while NWKHY trades at $7.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas NWKHY's P/E ratio is 10.70. In terms of profitability, DPAT's ROE is +0.45%, compared to NWKHY's ROE of +0.13%. Regarding short-term risk, DPAT and NWKHY have similar daily volatility (0.00).Check NWKHY's competition here
DPAT vs WHTCF Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, WHTCF has a market cap of 901.2M. Regarding current trading prices, DPAT is priced at $0.02, while WHTCF trades at $3.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas WHTCF's P/E ratio is -10.17. In terms of profitability, DPAT's ROE is +0.45%, compared to WHTCF's ROE of -0.15%. Regarding short-term risk, DPAT is less volatile compared to WHTCF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check WHTCF's competition here
DPAT vs EXETF Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, EXETF has a market cap of 805.5M. Regarding current trading prices, DPAT is priced at $0.02, while EXETF trades at $9.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas EXETF's P/E ratio is 13.73. In terms of profitability, DPAT's ROE is +0.45%, compared to EXETF's ROE of +0.65%. Regarding short-term risk, DPAT and EXETF have similar daily volatility (0.00).Check EXETF's competition here
DPAT vs JXFGF Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, JXFGF has a market cap of 755.6M. Regarding current trading prices, DPAT is priced at $0.02, while JXFGF trades at $0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas JXFGF's P/E ratio is 14.00. In terms of profitability, DPAT's ROE is +0.45%, compared to JXFGF's ROE of +0.03%. Regarding short-term risk, DPAT is less volatile compared to JXFGF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check JXFGF's competition here
DPAT vs KDGTF Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, KDGTF has a market cap of 675.1M. Regarding current trading prices, DPAT is priced at $0.02, while KDGTF trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas KDGTF's P/E ratio is -1.67. In terms of profitability, DPAT's ROE is +0.45%, compared to KDGTF's ROE of N/A. Regarding short-term risk, DPAT and KDGTF have similar daily volatility (0.00).Check KDGTF's competition here
DPAT vs ORRRY Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, ORRRY has a market cap of 371.5M. Regarding current trading prices, DPAT is priced at $0.02, while ORRRY trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas ORRRY's P/E ratio is -0.33. In terms of profitability, DPAT's ROE is +0.45%, compared to ORRRY's ROE of +7.04%. Regarding short-term risk, DPAT and ORRRY have similar daily volatility (0.00).Check ORRRY's competition here
DPAT vs BTMDW Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, BTMDW has a market cap of 292.9M. Regarding current trading prices, DPAT is priced at $0.02, while BTMDW trades at $1.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas BTMDW's P/E ratio is 0.05. In terms of profitability, DPAT's ROE is +0.45%, compared to BTMDW's ROE of -0.31%. Regarding short-term risk, DPAT is less volatile compared to BTMDW. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check BTMDW's competition here
DPAT vs EVGRF Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, EVGRF has a market cap of 236M. Regarding current trading prices, DPAT is priced at $0.02, while EVGRF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas EVGRF's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to EVGRF's ROE of +0.21%. Regarding short-term risk, DPAT is less volatile compared to EVGRF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check EVGRF's competition here
DPAT vs MKLNF Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, MKLNF has a market cap of 217.6M. Regarding current trading prices, DPAT is priced at $0.02, while MKLNF trades at $11.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas MKLNF's P/E ratio is 19.23. In terms of profitability, DPAT's ROE is +0.45%, compared to MKLNF's ROE of +0.14%. Regarding short-term risk, DPAT and MKLNF have similar daily volatility (0.00).Check MKLNF's competition here
DPAT vs MFCSF Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, MFCSF has a market cap of 198.6M. Regarding current trading prices, DPAT is priced at $0.02, while MFCSF trades at $10.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas MFCSF's P/E ratio is 5.66. In terms of profitability, DPAT's ROE is +0.45%, compared to MFCSF's ROE of +0.90%. Regarding short-term risk, DPAT and MFCSF have similar daily volatility (0.00).Check MFCSF's competition here
DPAT vs CHHHF Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, CHHHF has a market cap of 135M. Regarding current trading prices, DPAT is priced at $0.02, while CHHHF trades at $2.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas CHHHF's P/E ratio is -107.00. In terms of profitability, DPAT's ROE is +0.45%, compared to CHHHF's ROE of -0.02%. Regarding short-term risk, DPAT is less volatile compared to CHHHF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check CHHHF's competition here
DPAT vs COLRF Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, COLRF has a market cap of 123M. Regarding current trading prices, DPAT is priced at $0.02, while COLRF trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas COLRF's P/E ratio is -8.00. In terms of profitability, DPAT's ROE is +0.45%, compared to COLRF's ROE of +0.01%. Regarding short-term risk, DPAT is less volatile compared to COLRF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check COLRF's competition here
DPAT vs VTIAF Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, VTIAF has a market cap of 95.9M. Regarding current trading prices, DPAT is priced at $0.02, while VTIAF trades at $5.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas VTIAF's P/E ratio is -6.87. In terms of profitability, DPAT's ROE is +0.45%, compared to VTIAF's ROE of -0.63%. Regarding short-term risk, DPAT is less volatile compared to VTIAF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check VTIAF's competition here
DPAT vs MCIOF Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, MCIOF has a market cap of 54M. Regarding current trading prices, DPAT is priced at $0.02, while MCIOF trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas MCIOF's P/E ratio is -1.22. In terms of profitability, DPAT's ROE is +0.45%, compared to MCIOF's ROE of N/A. Regarding short-term risk, DPAT and MCIOF have similar daily volatility (0.00).Check MCIOF's competition here
DPAT vs ASSF Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, ASSF has a market cap of 45.3M. Regarding current trading prices, DPAT is priced at $0.02, while ASSF trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas ASSF's P/E ratio is -33.33. In terms of profitability, DPAT's ROE is +0.45%, compared to ASSF's ROE of -6.63%. Regarding short-term risk, DPAT and ASSF have similar daily volatility (0.00).Check ASSF's competition here
DPAT vs KONEF Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, KONEF has a market cap of 44.3M. Regarding current trading prices, DPAT is priced at $0.02, while KONEF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas KONEF's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to KONEF's ROE of -6.56%. Regarding short-term risk, DPAT is less volatile compared to KONEF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check KONEF's competition here
DPAT vs USNU Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, USNU has a market cap of 22.2M. Regarding current trading prices, DPAT is priced at $0.02, while USNU trades at $1.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas USNU's P/E ratio is -9.41. In terms of profitability, DPAT's ROE is +0.45%, compared to USNU's ROE of -0.55%. Regarding short-term risk, DPAT is less volatile compared to USNU. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check USNU's competition here
DPAT vs NVLPF Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, NVLPF has a market cap of 20.8M. Regarding current trading prices, DPAT is priced at $0.02, while NVLPF trades at $0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas NVLPF's P/E ratio is 23.82. In terms of profitability, DPAT's ROE is +0.45%, compared to NVLPF's ROE of +0.01%. Regarding short-term risk, DPAT and NVLPF have similar daily volatility (0.00).Check NVLPF's competition here
DPAT vs HQDA Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, HQDA has a market cap of 18.6M. Regarding current trading prices, DPAT is priced at $0.02, while HQDA trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas HQDA's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to HQDA's ROE of +0.00%. Regarding short-term risk, DPAT and HQDA have similar daily volatility (0.00).Check HQDA's competition here
DPAT vs FPCG Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, FPCG has a market cap of 10.1M. Regarding current trading prices, DPAT is priced at $0.02, while FPCG trades at $1,025.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas FPCG's P/E ratio is 0.09. In terms of profitability, DPAT's ROE is +0.45%, compared to FPCG's ROE of +0.00%. Regarding short-term risk, DPAT and FPCG have similar daily volatility (0.00).Check FPCG's competition here
DPAT vs NUMIF Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, NUMIF has a market cap of 9.9M. Regarding current trading prices, DPAT is priced at $0.02, while NUMIF trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas NUMIF's P/E ratio is -1.03. In terms of profitability, DPAT's ROE is +0.45%, compared to NUMIF's ROE of -2.96%. Regarding short-term risk, DPAT is less volatile compared to NUMIF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check NUMIF's competition here
DPAT vs HLYK Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, HLYK has a market cap of 7.9M. Regarding current trading prices, DPAT is priced at $0.02, while HLYK trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas HLYK's P/E ratio is -1.39. In terms of profitability, DPAT's ROE is +0.45%, compared to HLYK's ROE of +1.42%. Regarding short-term risk, DPAT is less volatile compared to HLYK. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check HLYK's competition here
DPAT vs GBCS Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, GBCS has a market cap of 7.7M. Regarding current trading prices, DPAT is priced at $0.02, while GBCS trades at $2.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas GBCS's P/E ratio is -2.40. In terms of profitability, DPAT's ROE is +0.45%, compared to GBCS's ROE of +0.55%. Regarding short-term risk, DPAT is less volatile compared to GBCS. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check GBCS's competition here
DPAT vs XCRT Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, XCRT has a market cap of 6.8M. Regarding current trading prices, DPAT is priced at $0.02, while XCRT trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas XCRT's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to XCRT's ROE of +0.90%. Regarding short-term risk, DPAT is less volatile compared to XCRT. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check XCRT's competition here
DPAT vs BICX Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, BICX has a market cap of 6.3M. Regarding current trading prices, DPAT is priced at $0.02, while BICX trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas BICX's P/E ratio is -1.00. In terms of profitability, DPAT's ROE is +0.45%, compared to BICX's ROE of +0.39%. Regarding short-term risk, DPAT and BICX have similar daily volatility (0.00).Check BICX's competition here
DPAT vs VLXC Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, VLXC has a market cap of 5.7M. Regarding current trading prices, DPAT is priced at $0.02, while VLXC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas VLXC's P/E ratio is -8.00. In terms of profitability, DPAT's ROE is +0.45%, compared to VLXC's ROE of +0.58%. Regarding short-term risk, DPAT is less volatile compared to VLXC. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check VLXC's competition here
DPAT vs RVLWF Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, RVLWF has a market cap of 5.3M. Regarding current trading prices, DPAT is priced at $0.02, while RVLWF trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas RVLWF's P/E ratio is -0.30. In terms of profitability, DPAT's ROE is +0.45%, compared to RVLWF's ROE of +3.95%. Regarding short-term risk, DPAT and RVLWF have similar daily volatility (0.00).Check RVLWF's competition here
DPAT vs RHEP Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, RHEP has a market cap of 3.9M. Regarding current trading prices, DPAT is priced at $0.02, while RHEP trades at $1.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas RHEP's P/E ratio is -0.76. In terms of profitability, DPAT's ROE is +0.45%, compared to RHEP's ROE of +1.14%. Regarding short-term risk, DPAT is less volatile compared to RHEP. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check RHEP's competition here
DPAT vs EPWCF Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, EPWCF has a market cap of 2.5M. Regarding current trading prices, DPAT is priced at $0.02, while EPWCF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas EPWCF's P/E ratio is -0.00. In terms of profitability, DPAT's ROE is +0.45%, compared to EPWCF's ROE of +0.00%. Regarding short-term risk, DPAT is less volatile compared to EPWCF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check EPWCF's competition here
DPAT vs GRST Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, GRST has a market cap of 2.3M. Regarding current trading prices, DPAT is priced at $0.02, while GRST trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas GRST's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to GRST's ROE of +0.28%. Regarding short-term risk, DPAT and GRST have similar daily volatility (0.00).Check GRST's competition here
DPAT vs TOKIF Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, TOKIF has a market cap of 1.8M. Regarding current trading prices, DPAT is priced at $0.02, while TOKIF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas TOKIF's P/E ratio is -0.01. In terms of profitability, DPAT's ROE is +0.45%, compared to TOKIF's ROE of -0.83%. Regarding short-term risk, DPAT is less volatile compared to TOKIF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check TOKIF's competition here
DPAT vs SMAS Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, SMAS has a market cap of 1.5M. Regarding current trading prices, DPAT is priced at $0.02, while SMAS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas SMAS's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to SMAS's ROE of N/A. Regarding short-term risk, DPAT is less volatile compared to SMAS. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check SMAS's competition here
DPAT vs MDGP Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, MDGP has a market cap of 1.5M. Regarding current trading prices, DPAT is priced at $0.02, while MDGP trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas MDGP's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to MDGP's ROE of -2.19%. Regarding short-term risk, DPAT and MDGP have similar daily volatility (0.00).Check MDGP's competition here
DPAT vs NOVC Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, NOVC has a market cap of 1.2M. Regarding current trading prices, DPAT is priced at $0.02, while NOVC trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas NOVC's P/E ratio is -0.20. In terms of profitability, DPAT's ROE is +0.45%, compared to NOVC's ROE of +0.12%. Regarding short-term risk, DPAT and NOVC have similar daily volatility (0.00).Check NOVC's competition here
DPAT vs PHMB Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, PHMB has a market cap of 1.1M. Regarding current trading prices, DPAT is priced at $0.02, while PHMB trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas PHMB's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to PHMB's ROE of N/A. Regarding short-term risk, DPAT is less volatile compared to PHMB. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check PHMB's competition here
DPAT vs JNHMF Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, JNHMF has a market cap of 870.6K. Regarding current trading prices, DPAT is priced at $0.02, while JNHMF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas JNHMF's P/E ratio is -0.17. In terms of profitability, DPAT's ROE is +0.45%, compared to JNHMF's ROE of +0.47%. Regarding short-term risk, DPAT is less volatile compared to JNHMF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check JNHMF's competition here
DPAT vs GNOW Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, GNOW has a market cap of 859.7K. Regarding current trading prices, DPAT is priced at $0.02, while GNOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas GNOW's P/E ratio is -0.01. In terms of profitability, DPAT's ROE is +0.45%, compared to GNOW's ROE of +0.00%. Regarding short-term risk, DPAT and GNOW have similar daily volatility (0.00).Check GNOW's competition here
DPAT vs ERUC Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, ERUC has a market cap of 638.1K. Regarding current trading prices, DPAT is priced at $0.02, while ERUC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas ERUC's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to ERUC's ROE of N/A. Regarding short-term risk, DPAT and ERUC have similar daily volatility (0.00).Check ERUC's competition here
DPAT vs JRSS Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, JRSS has a market cap of 507.6K. Regarding current trading prices, DPAT is priced at $0.02, while JRSS trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas JRSS's P/E ratio is -0.06. In terms of profitability, DPAT's ROE is +0.45%, compared to JRSS's ROE of +1.88%. Regarding short-term risk, DPAT is less volatile compared to JRSS. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check JRSS's competition here
DPAT vs MSITF Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, MSITF has a market cap of 480K. Regarding current trading prices, DPAT is priced at $0.02, while MSITF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas MSITF's P/E ratio is -0.10. In terms of profitability, DPAT's ROE is +0.45%, compared to MSITF's ROE of N/A. Regarding short-term risk, DPAT is less volatile compared to MSITF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check MSITF's competition here
DPAT vs FCHS Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, FCHS has a market cap of 395.5K. Regarding current trading prices, DPAT is priced at $0.02, while FCHS trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas FCHS's P/E ratio is -0.13. In terms of profitability, DPAT's ROE is +0.45%, compared to FCHS's ROE of +0.08%. Regarding short-term risk, DPAT is less volatile compared to FCHS. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check FCHS's competition here
DPAT vs KJFI Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, KJFI has a market cap of 374.6K. Regarding current trading prices, DPAT is priced at $0.02, while KJFI trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas KJFI's P/E ratio is -0.06. In terms of profitability, DPAT's ROE is +0.45%, compared to KJFI's ROE of +0.00%. Regarding short-term risk, DPAT is less volatile compared to KJFI. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check KJFI's competition here
DPAT vs ARPC Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, ARPC has a market cap of 336.6K. Regarding current trading prices, DPAT is priced at $0.02, while ARPC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas ARPC's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to ARPC's ROE of +3.10%. Regarding short-term risk, DPAT is less volatile compared to ARPC. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check ARPC's competition here
DPAT vs NXGT Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, NXGT has a market cap of 332.9K. Regarding current trading prices, DPAT is priced at $0.02, while NXGT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas NXGT's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to NXGT's ROE of +0.06%. Regarding short-term risk, DPAT is less volatile compared to NXGT. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check NXGT's competition here
DPAT vs BNYN Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, BNYN has a market cap of 286K. Regarding current trading prices, DPAT is priced at $0.02, while BNYN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas BNYN's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to BNYN's ROE of -14.10%. Regarding short-term risk, DPAT is less volatile compared to BNYN. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check BNYN's competition here
DPAT vs DRWN Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, DRWN has a market cap of 239.8K. Regarding current trading prices, DPAT is priced at $0.02, while DRWN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas DRWN's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to DRWN's ROE of -0.01%. Regarding short-term risk, DPAT is less volatile compared to DRWN. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check DRWN's competition here
DPAT vs SETO Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, SETO has a market cap of 160.9K. Regarding current trading prices, DPAT is priced at $0.02, while SETO trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas SETO's P/E ratio is -1.29. In terms of profitability, DPAT's ROE is +0.45%, compared to SETO's ROE of +0.00%. Regarding short-term risk, DPAT and SETO have similar daily volatility (0.00).Check SETO's competition here
DPAT vs TPIA Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, TPIA has a market cap of 113.8K. Regarding current trading prices, DPAT is priced at $0.02, while TPIA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas TPIA's P/E ratio is -0.15. In terms of profitability, DPAT's ROE is +0.45%, compared to TPIA's ROE of +0.60%. Regarding short-term risk, DPAT is less volatile compared to TPIA. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check TPIA's competition here
DPAT vs AMBD Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, AMBD has a market cap of 85.6K. Regarding current trading prices, DPAT is priced at $0.02, while AMBD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas AMBD's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to AMBD's ROE of +1.11%. Regarding short-term risk, DPAT is less volatile compared to AMBD. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check AMBD's competition here
DPAT vs NMHLY Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, NMHLY has a market cap of 41.7K. Regarding current trading prices, DPAT is priced at $0.02, while NMHLY trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas NMHLY's P/E ratio is 0.02. In terms of profitability, DPAT's ROE is +0.45%, compared to NMHLY's ROE of N/A. Regarding short-term risk, DPAT and NMHLY have similar daily volatility (0.00).Check NMHLY's competition here
DPAT vs CLRD Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, CLRD has a market cap of 32.5K. Regarding current trading prices, DPAT is priced at $0.02, while CLRD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas CLRD's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to CLRD's ROE of +0.38%. Regarding short-term risk, DPAT is less volatile compared to CLRD. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check CLRD's competition here
DPAT vs HSMD Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, HSMD has a market cap of 19.2K. Regarding current trading prices, DPAT is priced at $0.02, while HSMD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas HSMD's P/E ratio is -0.01. In terms of profitability, DPAT's ROE is +0.45%, compared to HSMD's ROE of -0.04%. Regarding short-term risk, DPAT and HSMD have similar daily volatility (0.00).Check HSMD's competition here
DPAT vs SCAL Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, SCAL has a market cap of 17.4K. Regarding current trading prices, DPAT is priced at $0.02, while SCAL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas SCAL's P/E ratio is 0.04. In terms of profitability, DPAT's ROE is +0.45%, compared to SCAL's ROE of +0.07%. Regarding short-term risk, DPAT and SCAL have similar daily volatility (0.00).Check SCAL's competition here
DPAT vs CEVE Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, CEVE has a market cap of 15.4K. Regarding current trading prices, DPAT is priced at $0.02, while CEVE trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas CEVE's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to CEVE's ROE of +2.26%. Regarding short-term risk, DPAT and CEVE have similar daily volatility (0.00).Check CEVE's competition here
DPAT vs GENN Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, GENN has a market cap of 12.1K. Regarding current trading prices, DPAT is priced at $0.02, while GENN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas GENN's P/E ratio is -0.01. In terms of profitability, DPAT's ROE is +0.45%, compared to GENN's ROE of +0.00%. Regarding short-term risk, DPAT is less volatile compared to GENN. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check GENN's competition here
DPAT vs CHCR Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, CHCR has a market cap of 12K. Regarding current trading prices, DPAT is priced at $0.02, while CHCR trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas CHCR's P/E ratio is -0.00. In terms of profitability, DPAT's ROE is +0.45%, compared to CHCR's ROE of N/A. Regarding short-term risk, DPAT and CHCR have similar daily volatility (0.00).Check CHCR's competition here
DPAT vs ACGI Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, ACGI has a market cap of 10.5K. Regarding current trading prices, DPAT is priced at $0.02, while ACGI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas ACGI's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to ACGI's ROE of +1.11%. Regarding short-term risk, DPAT is less volatile compared to ACGI. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check ACGI's competition here
DPAT vs NRTSF Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, NRTSF has a market cap of 7.8K. Regarding current trading prices, DPAT is priced at $0.02, while NRTSF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas NRTSF's P/E ratio is 0.01. In terms of profitability, DPAT's ROE is +0.45%, compared to NRTSF's ROE of +0.00%. Regarding short-term risk, DPAT is less volatile compared to NRTSF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check NRTSF's competition here
DPAT vs NAFS Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, NAFS has a market cap of 7K. Regarding current trading prices, DPAT is priced at $0.02, while NAFS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas NAFS's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to NAFS's ROE of +1.02%. Regarding short-term risk, DPAT and NAFS have similar daily volatility (0.00).Check NAFS's competition here
DPAT vs PRMD Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, PRMD has a market cap of 5.6K. Regarding current trading prices, DPAT is priced at $0.02, while PRMD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas PRMD's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to PRMD's ROE of +0.73%. Regarding short-term risk, DPAT is less volatile compared to PRMD. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check PRMD's competition here
DPAT vs MSGP Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, MSGP has a market cap of 5.2K. Regarding current trading prices, DPAT is priced at $0.02, while MSGP trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas MSGP's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to MSGP's ROE of +0.27%. Regarding short-term risk, DPAT and MSGP have similar daily volatility (0.00).Check MSGP's competition here
DPAT vs SLHPF Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, SLHPF has a market cap of 3.9K. Regarding current trading prices, DPAT is priced at $0.02, while SLHPF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas SLHPF's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to SLHPF's ROE of +0.00%. Regarding short-term risk, DPAT is less volatile compared to SLHPF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check SLHPF's competition here
DPAT vs WEQL Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, WEQL has a market cap of 3.5K. Regarding current trading prices, DPAT is priced at $0.02, while WEQL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas WEQL's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to WEQL's ROE of +0.21%. Regarding short-term risk, DPAT and WEQL have similar daily volatility (0.00).Check WEQL's competition here
DPAT vs BBAL Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, BBAL has a market cap of 3.4K. Regarding current trading prices, DPAT is priced at $0.02, while BBAL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas BBAL's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to BBAL's ROE of +0.45%. Regarding short-term risk, DPAT and BBAL have similar daily volatility (0.00).Check BBAL's competition here
DPAT vs PAOG Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, PAOG has a market cap of 2.5K. Regarding current trading prices, DPAT is priced at $0.02, while PAOG trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas PAOG's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to PAOG's ROE of +0.05%. Regarding short-term risk, DPAT is less volatile compared to PAOG. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check PAOG's competition here
DPAT vs NMMCF Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, NMMCF has a market cap of 2.1K. Regarding current trading prices, DPAT is priced at $0.02, while NMMCF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas NMMCF's P/E ratio is 0.00. In terms of profitability, DPAT's ROE is +0.45%, compared to NMMCF's ROE of +0.00%. Regarding short-term risk, DPAT is less volatile compared to NMMCF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check NMMCF's competition here
DPAT vs PPRG Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, PPRG has a market cap of 1.6K. Regarding current trading prices, DPAT is priced at $0.02, while PPRG trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas PPRG's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to PPRG's ROE of -0.58%. Regarding short-term risk, DPAT and PPRG have similar daily volatility (0.00).Check PPRG's competition here
DPAT vs OHAQ Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, OHAQ has a market cap of 1.4K. Regarding current trading prices, DPAT is priced at $0.02, while OHAQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas OHAQ's P/E ratio is 0.01. In terms of profitability, DPAT's ROE is +0.45%, compared to OHAQ's ROE of +0.09%. Regarding short-term risk, DPAT and OHAQ have similar daily volatility (0.00).Check OHAQ's competition here
DPAT vs BNKL Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, BNKL has a market cap of 1.2K. Regarding current trading prices, DPAT is priced at $0.02, while BNKL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas BNKL's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to BNKL's ROE of -7.69%. Regarding short-term risk, DPAT and BNKL have similar daily volatility (0.00).Check BNKL's competition here
DPAT vs MAHN Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, MAHN has a market cap of 1.2K. Regarding current trading prices, DPAT is priced at $0.02, while MAHN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas MAHN's P/E ratio is 0.05. In terms of profitability, DPAT's ROE is +0.45%, compared to MAHN's ROE of N/A. Regarding short-term risk, DPAT is less volatile compared to MAHN. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check MAHN's competition here
DPAT vs SLHGF Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, SLHGF has a market cap of 398. Regarding current trading prices, DPAT is priced at $0.02, while SLHGF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas SLHGF's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to SLHGF's ROE of +0.00%. Regarding short-term risk, DPAT and SLHGF have similar daily volatility (0.00).Check SLHGF's competition here
DPAT vs NMSCA Comparison August 2025
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 481.6K. In comparison, NMSCA has a market cap of 275. Regarding current trading prices, DPAT is priced at $0.02, while NMSCA trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.00, whereas NMSCA's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to NMSCA's ROE of +0.02%. Regarding short-term risk, DPAT and NMSCA have similar daily volatility (0.00).Check NMSCA's competition here